Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
11 02 2019
Historique:
received: 01 08 2018
accepted: 21 12 2018
entrez: 12 2 2019
pubmed: 12 2 2019
medline: 25 8 2020
Statut: epublish

Résumé

The Piwi-like genes belong to the Argonaute gene family and are conserved in plants, animals and humans. In addition to their essential role in the germ line and as stem cell-associated genes, Piwi-like proteins play a role in different cancer types but have yet to be studied in renal cell carcinoma (RCC). We investigated tissue micro arrays (TMAs) with tumor samples of two independent cohorts of RCC patients (N = 265 and N = 345); we used immunohistochemistry to assess the protein expression of Piwi-like 1. Applying an immunoreactive score (IRS), we found Piwi-like 1 positivity (IRS > 0) in 28.3% and 14.8% of the tumors in cohorts 1 and 2, respectively. Piwi-like 1 positivity was correlated with Fuhrman grade, tumor stage and the presence of distant metastasis (P < 0.005). Moreover, in univariate and multivariate analyses (adjusted to Fuhrman grade and tumor stage), Piwi-like 1 positivity was associated with a shorter cancer-specific survival in the patients in the second cohort. In addition, Piwi-like 1 expression allowed to further distinguish the RCC patients with high Fuhrman grade, high tumor stage, distant metastasis or high pre-operative levels of C-reactive protein, as Piwi-like 1 positivity was associated with a shorter cancer-specific survival in both cohorts. Our data encourage further investigations to enlighten the role of Piwi-like 1 and its function as a marker of poor prognosis in RCC patients.

Identifiants

pubmed: 30741998
doi: 10.1038/s41598-018-38254-3
pii: 10.1038/s41598-018-38254-3
pmc: PMC6370845
doi:

Substances chimiques

Argonaute Proteins 0
Biomarkers, Tumor 0
PIWIL1 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1741

Références

Curr Biol. 1999 Mar 11;9(5):R171-2
pubmed: 10074441
Blood. 2001 Jan 15;97(2):426-34
pubmed: 11154219
Genes Dev. 2002 Nov 1;16(21):2733-42
pubmed: 12414724
Genomics. 2003 Sep;82(3):323-30
pubmed: 12906857
Int J Cancer. 2006 Apr 15;118(8):1922-9
pubmed: 16287078
Genes Dev. 2007 Sep 15;21(18):2300-11
pubmed: 17875665
Onkologie. 2010;33(5):241-5
pubmed: 20502058
Cancer. 2012 May 15;118(10):2708-17
pubmed: 21989785
Nat Rev Genet. 2011 Nov 18;12(12):861-74
pubmed: 22094949
PLoS One. 2012;7(3):e33711
pubmed: 22438986
BMC Cancer. 2012 Sep 08;12:399
pubmed: 22958305
Front Genet. 2012 Oct 16;3:204
pubmed: 23087701
Nat Rev Genet. 2013 Jul;14(7):447-59
pubmed: 23732335
Biochim Biophys Acta. 2014 May;1842(5):686-90
pubmed: 24509249
Adv Exp Med Biol. 2014;825:159-97
pubmed: 25201106
Acta Biochim Biophys Sin (Shanghai). 2015 May;47(5):315-24
pubmed: 25854579
Mol Med. 2015 May 13;21:371-80
pubmed: 25998509
Dis Markers. 2015;2015:383056
pubmed: 26355242
Onco Targets Ther. 2016 Jan 08;9:217-22
pubmed: 26811690
Mol Med Rep. 2016 Mar;13(3):2829-35
pubmed: 26847393
Genes Dev. 2016 Jul 15;30(14):1623-35
pubmed: 27474441
Oncol Lett. 2017 May;13(5):3354-3362
pubmed: 28529570
Dis Markers. 2017;2017:1204937
pubmed: 28634417
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008
Development. 1997 Jun;124(12):2463-76
pubmed: 9199372
Genes Dev. 1998 Dec 1;12(23):3715-27
pubmed: 9851978

Auteurs

Christine G Stöhr (CG)

Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.

Sandra Steffens (S)

Clinic for Urology, University Hospital Muenster, Muenster, Germany.
Department of Urology, Hannover Medical School, Hannover, Germany.

Iris Polifka (I)

Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.

Rudolf Jung (R)

Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.

Andreas Kahlmeyer (A)

Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.

Philipp Ivanyi (P)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Florian Weber (F)

Institute of Pathology, University Regensburg, Regensburg, Germany.

Arndt Hartmann (A)

Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.

Bernd Wullich (B)

Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.

Sven Wach (S)

Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.

Helge Taubert (H)

Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany. helge.taubert@uk-erlangen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH